Coronary vasospasm
diseaseOn this page
Summary
Coronary vasospasm (MONDO:0005356) is a disease with 1 GWAS associations across 1 studies and 13 clinical trials. Top therapeutic interventions include diltiazem and nebivolol. A subtype of coronary artery disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 13
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | coronary vasospasm |
| Mondo ID | MONDO:0005356 |
| EFO | EFO:0004225 |
| MeSH | D003329 |
| DOID | DOID:11840 |
| SNOMED CT | 23687008 |
| UMLS | C0010073 |
| MedGen | 3626 |
| Is cancer (heuristic) | no |
Data availability: 1 GWAS association (1 study) · 3 cell lines.
Disease family
This is a subtype of coronary artery disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › coronary artery disorder › coronary vasospasm
Related subtypes (11): postoperative ventricular dysfunction, coronary aneurysm, coronary stenosis, coronary thrombosis, intermediate coronary syndrome, coronary artery disease, autosomal dominant, 1, coronary artery disease, autosomal dominant 2, coronary artery congenital malformation, coronary atherosclerosis, nonobstructive coronary artery disease, fibromuscular dysplasia of the coronary arteries
Subtypes (1): Prinzmetal angina
Genetics & variants
GWAS landscape
1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs10498345 | 9e-07 | CLEC14A - LINC00639 | T | 2.33 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST000125 | Suzuki S | 2007 | 50 | 0 | A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs10498345 | 14 | 38551301 | T>A | 0.3 | intron_variant | CLEC14A - LINC00639 | 9e-07 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Nifedipine | Approved (phase 4) |
| Sildenafil | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 13.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 10 |
| PHASE3 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03930433 | PHASE4 | COMPLETED | The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm |
| NCT04777045 | PHASE3 | ACTIVE_NOT_RECRUITING | Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial |
| NCT00454714 | PHASE3 | WITHDRAWN | Therapeutic Effect of Sildenafil in Patients With Coronary Vasospasm |
| NCT05288361 | Not specified | ACTIVE_NOT_RECRUITING | The DISCOVER INOCA Prospective Multi-center Registry |
| NCT06083155 | Not specified | ENROLLING_BY_INVITATION | The NetherLands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) |
| NCT06125392 | Not specified | RECRUITING | Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition |
| NCT00350129 | Not specified | COMPLETED | Effect of Glucose on Ocular Blood Flow |
| NCT00619294 | Not specified | COMPLETED | Endothelial Dysfunction and Coronary Artery Spasm |
| NCT00921856 | Not specified | UNKNOWN | Abnormal Coronary Vasomotion in Patients With Suspected Coronary Artery Disease (CAD) |
| NCT02298543 | Not specified | COMPLETED | Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry |
| NCT03193294 | Not specified | COMPLETED | CORonary MICrovascular Angina (CorMicA) |
| NCT04598308 | Not specified | UNKNOWN | EUROpean Coronary microCirculatory Resistance and Absolute Flow Trial |
| NCT05635994 | Not specified | UNKNOWN | Advanced Invasive Diagnosis for Patients With Chronic Coronary Syndromes Undergoing Coronary ANGIOgraphy (AID-ANGIO) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DILTIAZEM | 4 | 4 |
| NEBIVOLOL | 4 | 1 |
| CHEMBL2365658 | 0 | 1 |
| CHEMBL3526436 | 0 | 1 |